B

바이오니아

064550KOSDAQ

60.1 / 100

Reference Date: 2026-09-08

Financial Score14.0 / 40
News Sentiment19.1 / 25
Momentum17.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Surged 52.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

BioNia is a biopharmaceutical company specializing in developing solutions for disease diagnosis, treatment, and prevention based on core biotechnology, with key businesses in life science research products, molecular diagnostics, probiotics, and RNAi-based drug development. Over 33 years, it has accumulated advanced genetic technologies, supplying PCR equipment, molecular diagnostic kits, and expanding into new areas like synthetic biology bioprinting and RNA-based cosmetics.

Number of Employees

362people

Average Salary

52.4M KRW

Score Calculation Basis

Detailed Financial Score

PER
159.67Industry Average 15.000.0Point

10.6x industry avg (risky)

PBR
1.20Industry Average 1.204.0Point

In line with industry avg

ROE
0.75Industry Average 8.001.0Point

Well below industry avg

Debt Ratio
33.85Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20252.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲12.0% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼790.5% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -3.5% (improving, 3yr)

Detailed News Sentiment

11 totalPositive 8Neutral 1Negative 2Average Sentiment Score 76.4

Detailed Momentum

52-week position5.0Point

52w mid range (49%)

Current 10,560Won52-week high 15,50052-week low 5,790
1-month return6.0Point

1m +52.82% (strong rise)

Volume trend6.0Point

Volume surge

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral반기보고서 (2026.06)2026-08-14